Accessing Nuclear Receptors with ActiTarg-N

April 25, 2011 - PRLog -- Newark, DE. April, 2011 – Press Release - TimTec, LLC. – Accessing Nuclear Receptors with ActiTarg-N

TimTec adds new targeted library to its ActiTarg Series.  ActiTarg-N gathers 1040 nuclear receptors ligands analogs. Nuclear receptors are inside-cell proteins that regulate gene transcription and affect wide range of biological functions throughout organism normal and pathological development.  These are the super-family of 48 structurally related transcription factors that can be regulated by small molecules. The search for the small molecule or its defining features is one of the priorities of contemporary life-science R&D.  

TimTec uses “focused diversity” approach in designing the screening collection of nuclear receptor ligands analogs. Analogs compound pool started with about ninety “de-fragmented” known ligands. The following targets were primarily considered in the design:  ER, estrogen receptor and estrogen related receptor; AR, androgen receptor; GRR, glucocorticoid receptor;  RAR, retinoic acid receptor;  THR, thyroid hormone receptor;  VDR, vitamin D receptor;  FXR, Farnesoid X Receptor;  PPARa/y, Peroxisome proliferator-activated receptors;  LXR, liver X receptor;  CCR5, C-C chemokine receptor type 5; MRR, mineralocorticoid; PR,  progesterone receptor; CAR, Constitutive androstane receptor.

TimTec stock was scanned to identify molecules with the same known ligands fragments, which re-assembled themselves in the new combinations of chemical possibilities. Additional computational manipulations drew in more compounds with overall structural similarity to known molecules. As a result ActiTarg-N presents desirable chemical diversity with the sharp focus on the target group.

Contact for more information and free consultation scheduling:

TimTec LLC
Harmony Business Park A-301
Newark DE 19711
Tel 302 292 8500
Fax 302 292 8520
info@timtec.net

Web: http://www.timtec.net/actitarg-n-nuclear-receptor-ligands...

# # #

TimTec, evolved from a venture started by the Zelinsky Institute of Organic Chemistry (ZIOC) in Russia in the late 1980’s. Tremendous growth opportunities in the field of biological screening prompted us to establish operations in Europe and the US.